Cancer drug zongertinib tested for surprising side effects on other meds
NCT ID NCT06494761
First seen Jan 07, 2026
Summary
This completed phase 1 trial in 16 healthy men looked at whether taking multiple doses of the cancer drug zongertinib changes how the body processes three common drugs: midazolam (a sedative), omeprazole (for heartburn), and repaglinide (for diabetes). Participants received zongertinib daily for two weeks, along with single doses of the other drugs at specific times. The goal was to measure drug levels in the blood to see if zongertinib interferes with their breakdown, which could affect dosing in future patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zongertinib
What this could lead to
If successful, this study will show whether zongertinib changes how the body processes other common drugs, helping doctors adjust doses safely.
What could go wrong
This is a very early, small study in healthy volunteers, not patients. Results may not predict effects in people with cancer or those taking multiple medications.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.